Why the study?
Does renal denervation plus usual care reduce 24h systolic blood pressure and preserve glomerular filtration rate compared to usual care alone in treatment-resistant hypertensive patients?
Does renal denervation plus usual care reduce 24h systolic blood pressure and preserve glomerular filtration rate compared to usual care alone in treatment-resistant hypertensive patients?
The INSPiRED trial is designed to evaluate the long-term efficacy and safety of renal denervation compared to usual medical therapy in patients with treatment-resistant hypertension.
Answers are grounded in this paper and cite their sources.
INSPiRED will deliver long-term RCT data on renal denervation in resistant hypertension; extends prior trials with GFR preservation endpoint.
UNLABELLED: The SYMPLICITY studies showed that renal denervation (RDN) is feasible as novel treatment for resistant hypertension. However, RDN is a costly and invasive procedure, the long-term efficacy and safety of which has not yet been proven. Therefore, we designed the INSPiRED trial to compare the blood pressure lowering efficacy and safety of RDN vs usual medical therapy. INSPiRED is a randomized controlled trial enrolling 240 treatment-resistant hypertensive patients at 16 expert hypertension centres in Belgium. Eligible patients, aged 20-69 years old, have a 24-h ambulatory blood pressure of 130 mmHg systolic or 80 mmHg diastolic or more, while taking at least three antihypertensive drugs. They are randomized to RDN (EnligHTN(TM), SJM system) plus usual care (intervention group) or usual care alone (control group) in a ratio of 1:1. The primary endpoints for efficacy and safety, measured after 6 months, are the baseline-adjusted between-group differences in 24h systolic blood pressure and in glomerular filtration rate as estimated by the Chronic Kidney Disease Epidemiology Collaboration equation. Follow-up will continue up to 36 months after randomization. INSPiRED is powered to demonstrate a 10-mmHg difference in systolic blood pressure between randomized groups with a two-sided p-value of 0.01 and 90% power. It will generate long-term efficacy and safety data, identify the subset of treatment-resistant hypertensive patients responsive to RDN, provide information on cost-effectiveness, and by doing so INSPiRED will inform guideline committees and health policy makers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT 01505010.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: